Literature DB >> 31542837

Clinical and pathological features of immunoglobulin A nephropathy patients with nephrotic syndrome.

Xin Han1, Yi Xiao2, Yi Tang1, Xiaonan Zheng2, Mawluda Anwar2, Wei Qin3.   

Abstract

IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide. The classic manifestation of IgAN is episodic hematuria and proteinuria. Nephrotic syndrome (NS) is not very common in IgAN, reported to occur in only 5-10% of IgAN patients. However, the clinical and pathological characteristics and long-term outcomes of patients with NS-IgAN at onset remain unknown. A retrospective study was conducted, enrolling 1165 patients with biopsy-proven IgAN from West China Hospital in 2008-2015. Patients with renal biopsy of minimal change disease with mesangial IgA deposits were excluded. The renal endpoint was defined as 50% decrease in eGFR or progressing into end-stage renal disease (ESRD). A total of 1165 patients were enrolled with average age of 34.58, and 171 (14.7%) patients were presented with NS. Comparing NS and non-NS groups, significance differences were shown in hypertension (HTN), 24-h urine protein, serum albumin, serum creatine, eGFR and uric acid. NS group had severe pathological changes such as endocapillary hypercellularity, tubular atrophy or interstitial fibrosis and crescent, but less segmental glomerulosclerosis or adhesion and global sclerosis. During the average follow-up of 44.27 months, 29.8% (51/171) NS patients and 15.8% (157/994) non-NS patients progressed to the renal endpoint. 5-year renal survival rates were 73.1% and 87.8% (P < 0.001) in NS and non-NS groups, respectively. This study demonstrated that IgAN patients with NS had higher serum creatine, lower eGFR, lower uric acid, more acute lesions and poor prognosis. NS was an independent risk factor for progression to the renal endpoint.

Entities:  

Keywords:  End-stage renal disease (ESRD); IgA nephropathy; Nephrotic syndrome (NS)

Mesh:

Substances:

Year:  2019        PMID: 31542837     DOI: 10.1007/s10238-019-00580-9

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  32 in total

1.  Clinicopathological features and risk factors analysis of IgA nephropathy associated with acute kidney injury.

Authors:  Ling Zhang; Jianbo Li; Shicong Yang; Naya Huang; Qian Zhou; Qiongqiong Yang; Xueqing Yu
Journal:  Ren Fail       Date:  2016-04-06       Impact factor: 2.606

Review 2.  IgA nephropathy: an update.

Authors:  Maria F Soares; Ian S D Roberts
Journal:  Curr Opin Nephrol Hypertens       Date:  2017-05       Impact factor: 2.894

3.  [Intercapillary deposits of IgA-IgG].

Authors:  J Berger; N Hinglais
Journal:  J Urol Nephrol (Paris)       Date:  1968-09

Review 4.  Uric acid and the kidney.

Authors:  Sahar A Fathallah-Shaykh; Monica T Cramer
Journal:  Pediatr Nephrol       Date:  2013-07-04       Impact factor: 3.714

5.  Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial.

Authors:  K N Lai; F M Lai; C P Ho; K W Chan
Journal:  Clin Nephrol       Date:  1986-10       Impact factor: 0.975

6.  Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy.

Authors:  James V Donadio; Erik J Bergstralh; Joseph P Grande; Diana M Rademcher
Journal:  Nephrol Dial Transplant       Date:  2002-07       Impact factor: 5.992

7.  The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility.

Authors:  Ian S D Roberts; H Terence Cook; Stéphan Troyanov; Charles E Alpers; Alessandro Amore; Jonathan Barratt; Francois Berthoux; Stephen Bonsib; Jan A Bruijn; Daniel C Cattran; Rosanna Coppo; Vivette D'Agati; Giuseppe D'Amico; Steven Emancipator; Francesco Emma; John Feehally; Franco Ferrario; Fernando C Fervenza; Sandrine Florquin; Agnes Fogo; Colin C Geddes; Hermann-Josef Groene; Mark Haas; Andrew M Herzenberg; Prue A Hill; Ronald J Hogg; Stephen I Hsu; J Charles Jennette; Kensuke Joh; Bruce A Julian; Tetsuya Kawamura; Fernand M Lai; Lei-Shi Li; Philip K T Li; Zhi-Hong Liu; Bruce Mackinnon; Sergio Mezzano; F Paolo Schena; Yasuhiko Tomino; Patrick D Walker; Haiyan Wang; Jan J Weening; Nori Yoshikawa; Hong Zhang
Journal:  Kidney Int       Date:  2009-07-01       Impact factor: 10.612

8.  Remission of proteinuria improves prognosis in IgA nephropathy.

Authors:  Heather N Reich; Stéphan Troyanov; James W Scholey; Daniel C Cattran
Journal:  J Am Soc Nephrol       Date:  2007-10-31       Impact factor: 10.121

9.  Long-term outcome of IgA nephropathy with minimal change disease: a comparison between patients with and without minimal change disease.

Authors:  Xiao-Wei Li; Shao-Shan Liang; Wei-Bo Le; Shui-Qin Cheng; Cai-Hong Zeng; Jin-Quan Wang; Zhi-Hong Liu
Journal:  J Nephrol       Date:  2015-11-04       Impact factor: 3.902

10.  A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study.

Authors:  Masashi Goto; Kenji Wakai; Takashi Kawamura; Masahiko Ando; Masayuki Endoh; Yasuhiko Tomino
Journal:  Nephrol Dial Transplant       Date:  2009-06-10       Impact factor: 5.992

View more
  3 in total

1.  The difference between patients with nephrotic syndrome and nephrotic-range proteinuria in IgA nephropathy: a propensity score matched cohort study.

Authors:  Hongfen Li; Fanghao Wang; Junya Jia; Tiekun Yan; Youxia Liu; Shan Lin
Journal:  BMC Nephrol       Date:  2022-04-29       Impact factor: 2.585

2.  The clinical and pathological characteristics of IgA nephropathy patients in Tibet.

Authors:  Fenglei Si; Jiarong Mei; Yong A; Chen Tang; Yuxuan Yao; Lijun Liu
Journal:  BMC Nephrol       Date:  2022-07-27       Impact factor: 2.585

3.  Comparison between outcomes of IgA nephropathy with nephrotic-range proteinuria and nephrotic syndrome: do podocytes play a role?

Authors:  Yizhen Chen; Aicheng Yang; Yuansheng Hou; Longhui Liu; Jiehua Lin; Xiaodan Huang; Jundu Li; Xusheng Liu; Fuhua Lu; Qizhan Lin; Haifeng Yang; Shuling Yue; Shujun Jiang; Lixin Wang; Chuan Zou
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.